<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746745</url>
  </required_header>
  <id_info>
    <org_study_id>14892</org_study_id>
    <secondary_id>I4J-MC-HHBF</secondary_id>
    <nct_id>NCT01746745</nct_id>
  </id_info>
  <brief_title>A Study of LY2940680 in Healthy Participants</brief_title>
  <official_title>Disposition of [14C]-LY2940680 Following Oral Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single dose study of radiolabelled LY2940680 taken by mouth in healthy participants
      to study how the body absorbs and removes LY2940680 from the blood. This study is for
      research purposes only and is not intended to treat any medical condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fecal Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Predose up to 14 days postdose. Samples collected at 24-h intervals.</time_frame>
    <description>The percentage of the total radioactive dose administered that was excreted in feces = [(amount of radioactivity recovered in feces)/(radioactive dose administered)]*100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Predose up to 14 days postdose. Samples collected at 6-h intervals on Day 1 (0-6, 6-12, and 12-24 h postdose) and at 24-h intervals thereafter.</time_frame>
    <description>The percentage of the total radioactive dose administered that was excreted in urine=[(amount of radioactivity recovered in urine)/(radioactive dose administered)]*100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of LY2940680 and LSN3185556: Maximum Observed Concentration (Cmax)</measure>
    <time_frame>Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter</time_frame>
    <description>The Cmax of LY2940680 and its equipotent active metabolite in the free base form, LSN3185556, is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Radioactivity: Cmax</measure>
    <time_frame>Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of LY2940680, LSN3185556, and Radioactivity: Time of Maximum Observed Concentration (Tmax)</measure>
    <time_frame>Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.</time_frame>
    <description>The Tmax of LY2940680, LSN3185556, and total radioactivity in plasma are reported, as well as the Tmax for total radioactivity in whole blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of LY2940680 and LSN3185556: Area Under the Concentration-Time Curve From Time 0 to the Last Time Point With a Measurable Concentration [AUC(0 to Tlast)]</measure>
    <time_frame>Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Radioactivity: AUC(0 to Tlast)</measure>
    <time_frame>Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.</time_frame>
    <description>AUC(0 to Tlast) of total radioactivity in plasma and whole blood are reported in nanograms*hour equivalents per gram (ng*h Eq/g).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Plasma</measure>
    <time_frame>Day 1 up to 3 days postdose. Samples collected at 2, 3, 4, 6, and 8 h postdose on Day 1 and every 24 h thereafter.</time_frame>
    <description>Relative abundance was expressed and calculated as the percentage of plasma sample radioactivity=[(radioactivity in peak)/(radioactivity in sample)]*100. Metabolites with a relative abundance ≤6% are not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Urine</measure>
    <time_frame>Predose up to 4 days postdose. Samples collected at 6-h intervals on Day 1 (0-6, 6-12, and 12-24 h postdose) and at 24-h intervals thereafter.</time_frame>
    <description>Relative abundance was expressed and calculated as the percentage of administered dose excreted in urine=[(percentage of radioactivity in peak)/100]*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Abundance of LY2940680, the Metabolites of LY2940680, and LSN3185556 in Feces</measure>
    <time_frame>Predose up to 8 days postdose. Samples collected at 24-h intervals.</time_frame>
    <description>Relative abundance was expressed and calculated as the percentage of the administered dose excreted in feces=[(percentage of radioactivity in peak)/100]*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>[^14C]-LY2940680</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 100 milligram (mg) dose of LY2940680 containing 100 microCuries of carbon-14-labeled LY2940680 ([^14C]-LY2940680)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[^14C]-LY2940680</intervention_name>
    <description>Administered as solution by mouth</description>
    <arm_group_label>[^14C]-LY2940680</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy sterile males or surgically sterile females or postmenopausal
             females, as determined by medical history and laboratory assessments

          -  Have a body mass index (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m^2),
             inclusive

        Exclusion Criteria:

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Have consumed herbal supplements, grapefruit juice, grapefruits, grapefruit containing
             products, Seville orange juice, Seville oranges, star fruit, or star fruit juice
             within 7 days prior to dosing or intend to consume during the study

          -  Have donated blood of more than 500 milliliters (mL) within the last month

          -  Have participated in a [^14C]-study within the last 6 months prior to admission for
             this study

          -  Exposure to significant radiation within 12 months prior to dose (for example, serial
             X-ray or computed tomography scans, barium meal, current employment in a job requiring
             radiation exposure monitoring)

          -  Have a pattern less than once per 2 days to expel feces from the bowel through the
             rectum or acute constipation within 3 weeks of the day prior to dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 7, 2012</study_first_submitted>
  <study_first_submitted_qc>December 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <results_first_submitted>May 8, 2019</results_first_submitted>
  <results_first_submitted_qc>May 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2019</results_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants completed study at 14 days postdose or earlier if ≥90% of administered radioactivity recovered or 24-hour (h) urine and fecal samples from 2 consecutive collections each had radioactivity levels &lt;1.0% of total administered radioactivity in urine and feces combined.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>[^14C]-LY2940680</title>
          <description>Single 100-milligram (mg) LY2940680 dose containing 100 microCuries of carbon-14-labeled LY2940680 ([^14C]-LY2940680), administered as an oral solution.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled participants who received study drug and had at least 1 safety assessment postdose.</population>
      <group_list>
        <group group_id="B1">
          <title>[^14C]-LY2940680</title>
          <description>Single 100-mg LY2940680 dose containing 100 microCuries of [^14C]-LY2940680, administered as an oral solution.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>44 to 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fecal Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</title>
        <description>The percentage of the total radioactive dose administered that was excreted in feces = [(amount of radioactivity recovered in feces)/(radioactive dose administered)]*100.</description>
        <time_frame>Predose up to 14 days postdose. Samples collected at 24-h intervals.</time_frame>
        <population>Enrolled participants who received study drug and had evaluable pharmacokinetic (PK) data.</population>
        <group_list>
          <group group_id="O1">
            <title>[^14C]-LY2940680</title>
            <description>Single 100-mg LY2940680 dose containing 100 microCuries of [^14C]-LY2940680, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Fecal Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</title>
          <description>The percentage of the total radioactive dose administered that was excreted in feces = [(amount of radioactivity recovered in feces)/(radioactive dose administered)]*100.</description>
          <population>Enrolled participants who received study drug and had evaluable pharmacokinetic (PK) data.</population>
          <units>percentage of dose administered</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</title>
        <description>The percentage of the total radioactive dose administered that was excreted in urine=[(amount of radioactivity recovered in urine)/(radioactive dose administered)]*100.</description>
        <time_frame>Predose up to 14 days postdose. Samples collected at 6-h intervals on Day 1 (0-6, 6-12, and 12-24 h postdose) and at 24-h intervals thereafter.</time_frame>
        <population>Enrolled participants who received study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[^14C]-LY2940680</title>
            <description>Single 100-mg LY2940680 dose containing 100 microCuries of [^14C]-LY2940680, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</title>
          <description>The percentage of the total radioactive dose administered that was excreted in urine=[(amount of radioactivity recovered in urine)/(radioactive dose administered)]*100.</description>
          <population>Enrolled participants who received study drug and had evaluable PK data.</population>
          <units>percentage of dose administered</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK of LY2940680 and LSN3185556: Maximum Observed Concentration (Cmax)</title>
        <description>The Cmax of LY2940680 and its equipotent active metabolite in the free base form, LSN3185556, is reported.</description>
        <time_frame>Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter</time_frame>
        <population>Enrolled participants who received study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[^14C]-LY2940680</title>
            <description>Single 100-mg LY2940680 dose containing 100 microCuries of [^14C]-LY2940680, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK of LY2940680 and LSN3185556: Maximum Observed Concentration (Cmax)</title>
          <description>The Cmax of LY2940680 and its equipotent active metabolite in the free base form, LSN3185556, is reported.</description>
          <population>Enrolled participants who received study drug and had evaluable PK data.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma LY2940680</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="831" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma LSN3185556</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1210" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Radioactivity: Cmax</title>
        <time_frame>Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.</time_frame>
        <population>Enrolled participants who received study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[^14C]-LY2940680</title>
            <description>Single 100-mg LY2940680 dose containing 100 microCuries of [^14C]-LY2940680, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Radioactivity: Cmax</title>
          <population>Enrolled participants who received study drug and had evaluable PK data.</population>
          <units>nanogram equivalents per gram (ng Eq/g)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2380" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole Blood Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1520" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of LY2940680, LSN3185556, and Radioactivity: Time of Maximum Observed Concentration (Tmax)</title>
        <description>The Tmax of LY2940680, LSN3185556, and total radioactivity in plasma are reported, as well as the Tmax for total radioactivity in whole blood.</description>
        <time_frame>Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.</time_frame>
        <population>Enrolled participants who received study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[^14C]-LY2940680</title>
            <description>Single 100-mg LY2940680 dose containing 100 microCuries of [^14C]-LY2940680, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of LY2940680, LSN3185556, and Radioactivity: Time of Maximum Observed Concentration (Tmax)</title>
          <description>The Tmax of LY2940680, LSN3185556, and total radioactivity in plasma are reported, as well as the Tmax for total radioactivity in whole blood.</description>
          <population>Enrolled participants who received study drug and had evaluable PK data.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma LY2940680</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma LSN3185556</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="2.00" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole Blood Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PK of LY2940680 and LSN3185556: Area Under the Concentration-Time Curve From Time 0 to the Last Time Point With a Measurable Concentration [AUC(0 to Tlast)]</title>
        <time_frame>Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.</time_frame>
        <population>Enrolled participants who received study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[^14C]-LY2940680</title>
            <description>Single 100-mg LY2940680 dose containing 100 microCuries of [^14C]-LY2940680, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PK of LY2940680 and LSN3185556: Area Under the Concentration-Time Curve From Time 0 to the Last Time Point With a Measurable Concentration [AUC(0 to Tlast)]</title>
          <population>Enrolled participants who received study drug and had evaluable PK data.</population>
          <units>nanograms*hour per milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma LY2940680</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5680" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma LSN3185556</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20400" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Radioactivity: AUC(0 to Tlast)</title>
        <description>AUC(0 to Tlast) of total radioactivity in plasma and whole blood are reported in nanograms*hour equivalents per gram (ng*h Eq/g).</description>
        <time_frame>Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.</time_frame>
        <population>Enrolled participants who received study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[^14C]-LY2940680</title>
            <description>Single 100-mg LY2940680 dose containing 100 microCuries of [^14C]-LY2940680, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Radioactivity: AUC(0 to Tlast)</title>
          <description>AUC(0 to Tlast) of total radioactivity in plasma and whole blood are reported in nanograms*hour equivalents per gram (ng*h Eq/g).</description>
          <population>Enrolled participants who received study drug and had evaluable PK data.</population>
          <units>ng*h Eq/g</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64800" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole Blood Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38200" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Plasma</title>
        <description>Relative abundance was expressed and calculated as the percentage of plasma sample radioactivity=[(radioactivity in peak)/(radioactivity in sample)]*100. Metabolites with a relative abundance ≤6% are not reported.</description>
        <time_frame>Day 1 up to 3 days postdose. Samples collected at 2, 3, 4, 6, and 8 h postdose on Day 1 and every 24 h thereafter.</time_frame>
        <population>Enrolled participants who received study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[^14C]-LY2940680</title>
            <description>Single 100-mg LY2940680 dose containing 100 microCuries of [^14C]-LY2940680, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Plasma</title>
          <description>Relative abundance was expressed and calculated as the percentage of plasma sample radioactivity=[(radioactivity in peak)/(radioactivity in sample)]*100. Metabolites with a relative abundance ≤6% are not reported.</description>
          <population>Enrolled participants who received study drug and had evaluable PK data.</population>
          <units>percentage of sample radioactivity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LY2940680 (parent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M75 (LSN3185556)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Urine</title>
        <description>Relative abundance was expressed and calculated as the percentage of administered dose excreted in urine=[(percentage of radioactivity in peak)/100]*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.</description>
        <time_frame>Predose up to 4 days postdose. Samples collected at 6-h intervals on Day 1 (0-6, 6-12, and 12-24 h postdose) and at 24-h intervals thereafter.</time_frame>
        <population>Enrolled participants who received study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[^14C]-LY2940680</title>
            <description>Single 100-mg LY2940680 dose containing 100 microCuries of [^14C]-LY2940680, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Urine</title>
          <description>Relative abundance was expressed and calculated as the percentage of administered dose excreted in urine=[(percentage of radioactivity in peak)/100]*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.</description>
          <population>Enrolled participants who received study drug and had evaluable PK data.</population>
          <units>percentage of administered dose excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LY2940680 (parent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.105" spread="0.0937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="0.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Abundance of LY2940680, the Metabolites of LY2940680, and LSN3185556 in Feces</title>
        <description>Relative abundance was expressed and calculated as the percentage of the administered dose excreted in feces=[(percentage of radioactivity in peak)/100]*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.</description>
        <time_frame>Predose up to 8 days postdose. Samples collected at 24-h intervals.</time_frame>
        <population>Enrolled participants who received study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[^14C]-LY2940680</title>
            <description>Single 100-mg LY2940680 dose containing 100 microCuries of [^14C]-LY2940680, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Abundance of LY2940680, the Metabolites of LY2940680, and LSN3185556 in Feces</title>
          <description>Relative abundance was expressed and calculated as the percentage of the administered dose excreted in feces=[(percentage of radioactivity in peak)/100]*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.</description>
          <population>Enrolled participants who received study drug and had evaluable PK data.</population>
          <units>percentage of administered dose excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LY2940680 (parent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.431" spread="0.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="0.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LSN3185556</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>[^14C]-LY2940680</title>
          <description>Single 100-mg LY2940680 dose containing 100 microCuries of [^14C]-LY2940680, administered as an oral solution.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Soft tissue mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

